Drug Detail:Aminosalicylic acid (monograph) (Paser)
Drug Class:
Usual Adult Dose for Tuberculosis - Resistant
4 grams orally 3 times a day
Comment: If this drug is used in patients with proven/suspected drug resistance, it should be used with at least 1 other agent to which the organism is susceptible.
Uses:
- Treatment of tuberculosis in combination with other active agents
- Treatment of multi-drug resistant tuberculosis (MDR-TB), or in situations when therapy with isoniazid or rifampin is not possible due to a combination of resistance and/or intolerance
American Thoracic Society (ATS), US Centers for Disease Control and Prevention (US CDC), and Infectious Diseases Society of America (IDSA) Recommendations:
4000 mg orally 2 to 3 times a day
- Maximum dose: 12 grams/day
Comment: There are inadequate data to support intermittent dosing.
Use: Second-line treatment of drug-susceptible tuberculosis caused by susceptible organisms
Usual Adult Dose for Tuberculosis - Active
4 grams orally 3 times a day
Comment: If this drug is used in patients with proven/suspected drug resistance, it should be used with at least 1 other agent to which the organism is susceptible.
Uses:
- Treatment of tuberculosis in combination with other active agents
- Treatment of multi-drug resistant tuberculosis (MDR-TB), or in situations when therapy with isoniazid or rifampin is not possible due to a combination of resistance and/or intolerance
American Thoracic Society (ATS), US Centers for Disease Control and Prevention (US CDC), and Infectious Diseases Society of America (IDSA) Recommendations:
4000 mg orally 2 to 3 times a day
- Maximum dose: 12 grams/day
Comment: There are inadequate data to support intermittent dosing.
Use: Second-line treatment of drug-susceptible tuberculosis caused by susceptible organisms
Usual Pediatric Dose for Tuberculosis - Resistant
ATS, US CDC, and IDSA Recommendations:
Children: 100 mg/kg orally 2 to 3 times a day
- Maximum dose: 300 mg/kg/day
Comment: There are inadequate data to support intermittent dosing.
Use: Second-line treatment of drug-susceptible tuberculosis caused by susceptible organisms
American Academy of Pediatrics (AAP) Recommendations:
Infants, Children, and Adolescents: 200 to 300 mg/kg orally per day, given in 2 to 4 divided doses
- Maximum dose: 10 grams/day
Use: Treatment of drug-resistant tuberculosis
Usual Pediatric Dose for Tuberculosis - Active
ATS, US CDC, and IDSA Recommendations:
Children: 100 mg/kg orally 2 to 3 times a day
- Maximum dose: 300 mg/kg/day
Comment: There are inadequate data to support intermittent dosing.
Use: Second-line treatment of drug-susceptible tuberculosis caused by susceptible organisms
American Academy of Pediatrics (AAP) Recommendations:
Infants, Children, and Adolescents: 200 to 300 mg/kg orally per day, given in 2 to 4 divided doses
- Maximum dose: 10 grams/day
Use: Treatment of drug-resistant tuberculosis
Renal Dose Adjustments
Mild to moderate renal dysfunction: Data not available
Severe renal dysfunction: Contraindicated
End-stage renal disease receiving dialysis: Use should be avoided.
Liver Dose Adjustments
Liver dysfunction: Data not available
Signs/symptoms of drug-induced hepatitis: Treatment should be stopped immediately.
Dose Adjustments
Liver dysfunction: Data not available
Signs/symptoms of drug-induced hepatitis: Treatment should be stopped immediately.
Precautions
CONTRAINDICATIONS:
- Hypersensitivity to the active component or any of the ingredients
- Severe renal dysfunction
Consult WARNINGS section for additional precautions.
Dialysis
Patients with end-stage renal disease receiving dialysis: Use should be avoided.
Other Comments
Administration advice:
- Granules should not be crushed or chewed.
- Packets and granules should be visually inspected before use.
Storage requirements:
- Store below 15C (in a refrigerator or freezer)
Reconstitution/preparation techniques:
- Suspend in an acidic drink or food with a pH of less than 5 (e.g., apple sauce, yogurt, tomato or orange juice) immediately prior to administration
General:
- This drug is not active against Mycobacterium avium.
Monitoring:
- Endocrine: Thyroid function in patients with HIV prior to starting and regularly during treatment, especially when given with ethionamide/prothionamide
- Hepatic: Regular hepatic function tests, especially during the first 3 months of treatment
- Hypersensitivity: Signs/symptoms of intolerance, especially during the first 3 months of treatment
Patient advice:
- Patients should be advised to avoid using swollen packets or granules that have changed color (e.g., dark brown or purple) or lost their tan coloring.
- Patients should be warned that granule skeletons may appear in feces.
- Advise patients to speak to their healthcare provider if they become pregnant, intend to become pregnant, or are breastfeeding.